German change highlights Stada’s consumer ambitions

German change highlights Stada’s consumer ambitions
Stada is “laying the foundation to combine all activities related to its branded products in a global consumer healthcare division”, says chief executive officer Peter Goldschmidt

8 July 2020 - Deborah Wilkes

Stada has changed the name of its German consumer healthcare business in a move that highlights the company’s ambitions.

Stada GmbH is now known as Stada Consumer Health Deutschland GmbH. The company said the move made it “clear at first glance” that the business stood for “strong branded products such as Grippostad, Ladival and Hoggar with a clear focus on consumers and pharmacists”.

Peter Goldschmidt, Stada’s chief executive officer, said Stada was “laying the foundation to combine all activities related to its branded products in a global consumer healthcare division”.

Bringing the company’s consumer healthcare activities into a single entity or division worldwide is a work in progress, which Stada says is “likely to require some time”.

Read all about Stada’s consumer healthcare strategy in a new NEWS EXTRA publication from OTCToolbox. Click here to download today.

Goldschmidt noted that Stada’s strategy was based on two pillars consisting of generics and non-prescription consumer healthcare products. He said “local, country-specific brands” were the key to success in the company’s consumer healthcare business.

In Germany, Stada now has three businesses. In addition to Stada Consumer Health Deutschland, Aliud Pharma focuses on generics and discount agreements while Stadapharm specialises in pharmaceuticals such as biosimilars and cytostatics.

Managing directors of the three businesses report to Eelco Ockers, Stada’s executive vice president Germany and a member of the worldwide executive committee.

Click tags below for more information on topics:

Stada

Back to Industry News

Share this page: